Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
15 studies found for:    paroxysmal nocturnal hemoglobinuria | Open Studies
Show Display Options
Download search resultsDownload the search results for:
paroxysmal nocturnal hemoglobinuria | Open Studies (15 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)
Condition: Paroxysmal Nocturnal Haemoglobinuria (PNH)
Intervention: Drug: Coversin
2 Recruiting A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention: Drug: ACH-0144471
3 Not yet recruiting ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: Biological: ALXN1210;   Biological: Eculizumab
4 Recruiting ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: Biological: ALXN1210;   Biological: Eculizumab
5 Recruiting Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention: Biological: LFG316
6 Recruiting Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. APL-2 in PNH Subjects
Condition: Paroxysmal Nocturnal Hemoglobinuria
Intervention: Drug: APL-2
7 Recruiting Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention: Drug: RA101495
8 Recruiting Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Intervention: Drug: RA101495
9 Recruiting Assessment of the Mutation of Pig-A Gene as Biomarker of Genotoxic Exposure in Humans
Condition: Patient With Breast Cancer
Intervention: Genetic: blood samples
10 Recruiting Unrelated And Partially Matched Related Donor PSCT w/ TCR αβ Depletion for Patients With BMF
Conditions: Acquired Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Inherited Bone Marrow Failure Syndromes
Intervention: Device: CliniMACs
11 Recruiting Unrelated Donor Stem Cell Transplantation
Conditions: Severe Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Syndromes;   Chronic Myelogenous Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Large Granulocytic Leukemia
Intervention: Procedure: Allogeneic transplantation
12 Recruiting Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies
Conditions: Sickle Cell Disease;   Transfusion Dependent Alpha- or Beta- Thalassemia;   Diamond Blackfan Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Glanzmann Thrombasthenia;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Non-Malignant Hematologic Disorders
Interventions: Drug: Reduced Toxicity Ablative Regimen;   Drug: Reduced Intensity Preparative Regimen;   Drug: Myeloablative Preparative Regimen
13 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Conditions: Severe Aplastic Anemia;   MDS (Myelodysplastic Syndrome)
Interventions: Device: Miltenyi CD34 Reagent System;   Other: Donor derived G-CSF mobilized PBC
14 Recruiting Natural History of Sickle Cell Disease
Condition: Sickle Cell Disease
Intervention:
15 Recruiting Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Conditions: Hematologic Disease;   Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome;   Myeloproliferative Disorder
Intervention: Procedure: Stem cell transplantation

Study has passed its completion date and status has not been verified in more than two years.